A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Study, to Assess the Safety and Tolerability of 28 Days Treatment With NVA237 (100 or 200microg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Study, to Assess the Safety and Tolerability of 28 Days Treatment With NVA237 (100 or 200microg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2015

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 24 Mar 2012 This trial is recruiting in France and Spain.
    • 07 Oct 2008 Results presented at the European Respiratory Society Annual Congress according to a Sosei Group Corporation media release.
    • 06 Oct 2008 Results have been presented at the European Respiratory Society Annual Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top